MedTrace Logo

Personalized DC Vaccine for Lung Cancer

NCT02956551 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-05-31

No results posted yet for this study

Summary

The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

DC vaccine

subcutaneous administration

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Zhen-Yu Ding, Prof · Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-12-31
Completion
2020-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02956551 on ClinicalTrials.gov